연구성과로 돌아가기
2021 연구성과 (208 / 281)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Zinc(II) and cadmium(II) coordination polymers with bis(4-pyridyl)benzylamine: structure and photoluminescence | Two coordination polymers, [(bpba)Zn(CH3COO)(2)](n) (1) and [(bpba)(3)Cd-2(NO3)(4)](n)center dot nMeOH center dot 4nH(2)O (2) (bpba = bis(4-pyridyl)benzylamine), were obtained using Zn(CH3COO)(2)center dot 2H(2)O/Cd(NO3)(2)center dot 4H(2)O and bpba in a mixture of solvents, and were further characterized. The zinc(II) ion of 1 showed a tetrahedral geometry with two oxygen atoms of the acetate ligands and two pyridine groups of the bpba ligands, and it is linked to the neighboring zinc(II) ions through the bpba ligands, giving rise to an interesting one-dimensional helical structure. Contrastingly, the cadmium(II) ion of polymer 2 was bonded by three pyridine groups of three different bpba ligands and four oxygen atoms of two nitrate ligands, exhibiting a T-shaped geometry. Thus, polymer 2 forms a two-dimensional wave-like structure by the coordination of cadmium(II) ion and bpba ligand to each other. Polymers 1 and 2 showed strong UV emissions depending on the metal ions and are red-shifted, compared to the bpba ligand. | Jeong, Ah Rim; Min, Kil Sik | Kyungpook Natl Univ, Dept Chem, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Chem Educ, Daegu 41566, South Korea | 56014521800; 7201466885 | minks@knu.ac.kr; | JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY | J INCL PHENOM MACRO | 1388-3127 | 1573-1111 | 101 | 3-4 | SCIE | CHEMISTRY, MULTIDISCIPLINARY | 2021 | 1.925 | 71.8 | 0.14 | 2025-07-30 | 3 | 3 | Coordination polymers; Zinc(II) polymers; Cadmium(II) polymers; Crystal structure; Photoluminescence | Cadmium(II) polymers; Coordination polymers; Crystal structure; Photoluminescence; Zinc(II) polymers | English | 2021 | 2021-12 | 10.1007/s10847-021-01058-6 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Review | Antiepileptic Drug Therapy for Status Epilepticus | Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy to rapidly terminate seizure activities. The Drug Committee of the Korean Epilepsy Society performed a review of existing guidelines and literature with the aim of providing practical recommendations for antiepileptic drug therapy. This article is one of a series of review articles by the Drug Committee and it summarizes staged antiepileptic drug therapy for SE. While evidence of good quality supports the use of benzodiazepines as the first-line treatment of SE, such evidence informing the administration of second- or third-line treatments is lacking; hence, the recommendations presented herein concerning the treatment of established and refractory SE are based on case series and expert opinions. The choice of antiepileptic drugs in each stage should consider the characteristics and circumstances of each patient, as well as their estimated benefit and risk to them. In tandem with the antiepileptic drug therapy, careful searching for and treatment of the underlying etiology are required. | Kim, Daeyoung; Kim, Jae-Moon; Cho, Yong Won; Yang, Kwang Ik; Kim, Dong Wook; Lee, Soon-Tae; No, Young Joo; Seo, Jong-Geun; Byun, Jung-Ick; Kang, Kyung Wook; Kim, Keun Tae | Chungnam Natl Univ, Chungnam Natl Univ Hosp, Dept Neurol, Coll Med, 282 Munhwa Ro, Daejeon 35015, South Korea; Keimyung Univ, Sch Med, Dept Neurol, 1095 Dalgubeol Daero, Daegu 42601, South Korea; Soonchunhyang Univ, Cheonan Hosp, Coll Med, Dept Neurol, Cheonan, South Korea; Konkuk Univ, Sch Med, Dept Neurol, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Neurol, Seoul, South Korea; Samsung Noble Cty, Dept Neurol, Yongin, South Korea; Kyungpook Natl Univ, Sch Med, Dept Neurol, Daegu, South Korea; Kyung Hee Univ Hosp Gangdong, Dept Neurol, Seoul, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Sch Med, Dept Neurol, Gwangju, South Korea | ; Kim, Yong-Jae/JQW-5758-2023; Lee, Soon-Tae/C-4663-2013; Kim, Keun Tae/IQU-1105-2023 | 57191361218; 34769781900; 55080335000; 55328263200; 57075285300; 8527655300; 6701791454; 16040307500; 55896913500; 57211333312; 57204465615 | jmoonkim@cnu.ac.kr;neurocho@gmail.com; | JOURNAL OF CLINICAL NEUROLOGY | J CLIN NEUROL | 1738-6586 | 2005-5013 | 17 | 1 | SCIE | CLINICAL NEUROLOGY | 2021 | 2.566 | 71.9 | 0.46 | 2025-07-30 | 11 | 13 | status epilepticus; seizure; antiepileptic drugs; benzodiazepines; anesthetics; drug therapy | REFRACTORY STATUS EPILEPTICUS; CONVULSIVE STATUS EPILEPTICUS; NONCONVULSIVE STATUS EPILEPTICUS; INTRAVENOUS PHENYTOIN; RANDOMIZED-TRIAL; LORAZEPAM; DIAZEPAM; SEIZURES; CLASSIFICATION; LACOSAMIDE | Anesthetics; Antiepileptic drugs; Benzodiazepines; Drug therapy; Seizure; Status epilepticus | anesthetic agent; anticonvulsive agent; benzodiazepine derivative; diazepam; fosphenytoin sodium; ketamine; lacosamide; levetiracetam; lorazepam; midazolam; phenobarbital; phenytoin; propofol; thiopental; valproic acid; convulsive therapy; electroencephalography; epileptic state; human; practice guideline; Review; risk assessment; seizure | English | 2021 | 2021-01 | 10.3988/jcn.2021.17.1.11 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia | Background and Purpose The rate of donepezil discontinuation and the underlying reasons for discontinuation in Asian patients with Alzheimer's disease (AD) are currently unknown. We aimed to determine the treatment discontinuation rates in AD patients who had newly been prescribed donepezil in routine clinical practice in Asia. Methods This 1-year observational study involved 38 institutions in seven Asian countries, and it evaluated 398 participants aged 50-90 years with a diagnosis of probable AD and on newly prescribed donepezil monotherapy. The primary endpoint was the rate of donepezil discontinuation over 1 year. Secondary endpoints included the reason for discontinuation, treatment duration, changes in cognitive function over the 1-year study period, and compliance as assessed using a clinician rating scale (CRS) and visual analog scale (VAS). Results Donepezil was discontinued in 83 (20.9%) patients, most commonly due to an adverse event (43.4%). The mean treatment duration was 103.67 days in patients who discontinued. Among patients whose cognitive function was assessed at baseline and 1 year, there were no significant changes in scores on the Mini-Mental State Examination, Montreal Cognitive Assessment, and Trail-Making Test-Black and White scores, whereas the Clinical Dementia Rating score increased significantly (p<0.001). Treatment compliance at 1 year was 96.8% (306/316) on the CRS and 92.6 +/- 14.1% (mean +/- standard deviation) on the VAS. Conclusions In patients on newly prescribed donepezil, the primary reason for discontinuation was an adverse event. Cognitive assessments revealed no significant worsening at 1 year, indicating that continuous donepezil treatment contributes to the maintenance of cognitive function. | Park, Kee Hyung; Yang, YoungSoon; Chen, Christopher; Shim, Yong S.; Domingueze, Jacqueline C.; Lee, Chan-Nyoung; Kang, Kyunghun; Kim, Hee-Jin; Jeong, Seul-Ki; Jeong, Jee Hyang; Hong, Zhen; Yoon, Soo Jin; Zhang, Zhen-Xin; Kim, Eun-Joo; Jang, Jae-Won; Li, Yansheng; Xu, Yun; Lin, Yu-Te; Qu, Qiumin; Hu, Chaur-Jong; Chou, Chih-Ho; Fan, Dongsheng; Kandiah, Nagaendran; Yang, Yuan-Han; Lau, Chi-ieong; Chu, Leung-Wing; Wang, Huali; Jung, San; Choi, Seong Hye; Kim, SangYun | Gachon Univ, Coll Med, Dept Neurol, Gil Hosp, Incheon, South Korea; Soonchunhyang Univ, Cheonan Hosp, Dept Neurol, Coll Med, Cheonan, South Korea; Natl Univ Singapore, Memory Aging & Cognit Ctr, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore; Natl Univ Singapore, Memory Aging & Cognit Ctr, Yong Loo Lin Sch Med, Dept Psychol Med, Singapore, Singapore; Catholic Univ Korea, Coll Med, Dept Neurol, Eunpyeong St Marys Hosp, Seoul, South Korea; St Lukes Med Ctr, Inst Neurosci, Taguig, Philippines; Korea Univ, Coll Med, Dept Neurol, Anam Hosp, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Neurol, Daegu, South Korea; Hanyang Univ, Coll Med, Dept Neurol, Seoul, South Korea; Chonbuk Natl Univ, Dept Neurol, Sch Med, Jeonju, South Korea; Ewha Womans Univ, Dept Neurol, Seoul Hosp, Seoul, South Korea; Fudan Univ, Huashan Hosp, Inst Neurol, Shanghai, Peoples R China; Eulji Univ, Eulji Univ Hosp, Dept Neurol, Sch Med, Daejeon, South Korea; Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurol, Beijing, Peoples R China; Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Neurol, Sch Med, Busan, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Neurol, Med Res Inst, Busan, South Korea; Kangwon Natl Univ, Kangwon Natl Univ Hosp, Dept Neurol, Coll Med, Chunchon, South Korea; Shanghai Jiao Tong Univ, Dept Neurol, Renji Hosp, Sch Med, Shanghai, Peoples R China; Nanjing Drum Tower Hosp, Nanjing, Peoples R China; Kaohsiung Vet Gen Hosp, Ctr Geriatr & Gerontol, Kaohsiung, Taiwan; Xi An Jiao Tong Univ, Dept Neurol, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, Dementia Ctr, Taipei, Taiwan; Taipei Med Univ, Coll Med, Sch Med, Taipei, Taiwan; Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; Peking Univ Third Hosp, Dept Neurol, Beijing, Peoples R China; Natl Neurosci Inst, Dept Neurol, Singapore, Singapore; Duke NUS Grad Med Sch, Singapore, Singapore; Lee Kong Chian Med Sch NTU, Singapore, Singapore; Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Neurol, Kaohsiung, Taiwan; Shin Kong Wu Ho Su Mem Hosp, Dept Neurol, Taipei, Taiwan; Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China; Peking Univ Inst Mental Hlth Sixth Hosp, Dementia Care & Res Ctr, Beijing, Peoples R China; Hallym Univ, Dept Neurol, Kangnam Sacred Heart Hosp, Seoul, South Korea; Inha Univ, Dept Neurol, Sch Med, Incheon, South Korea; Seoul Natl Univ, Dept Neurol, Coll Med, Seongnam, South Korea; Seoul Natl Univ, Bundang Hosp, Clin Neurosci Ctr, Seongnam, South Korea | Jeong, Seul-Ki/KSL-7574-2024; Kim, EunJoo/KIB-8989-2024; Chuang, Hung-Yi/C-9143-2009; Kim, Sang/J-5400-2012; Jeong, Seul-ki/KSL-7574-2024; Chen, Christopher/E-7023-2013; Kim, Hee-Jin/P-1903-2015; Wang, Huali/S-9848-2018; lin, yt/IQT-6771-2023; Yang, Yijian/G-1580-2016 | 7408065966; 37032348800; 57375362200; 26027624100; 15135804800; 54179516000; 55365592200; 58365187300; 8578821400; 7402045750; 7201414497; 55382315500; 8683583100; 57204538113; 56457145600; 55719155700; 57222657419; 57208634363; 7005835798; 7404569929; 57204000811; 7202965513; 24391293500; 36132623000; 36644418400; 7202236665; 7501749505; 9045212800; 15838894900; 7601593906 | neuroksy@snu.ac.kr; | JOURNAL OF CLINICAL NEUROLOGY | J CLIN NEUROL | 1738-6586 | 2005-5013 | 17 | 3 | SCIE | CLINICAL NEUROLOGY | 2021 | 2.566 | 71.9 | 0.46 | 2025-07-30 | 6 | 7 | Alzheimer's disease; Asia; cognition; donepezil | LONG-TERM EFFICACY; DOUBLE-BLIND; CHOLINESTERASE-INHIBITORS; US MULTICENTER; OPEN-LABEL; SAFETY; PERSISTENCE; ADHERENCE; MODERATE; DEMENTIA | Asia; Cognition; Donepezil; Alzheimer’s disease | English | 2021 | 2021-07 | 10.3988/jcn.2021.17.3.376 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study | Background and Purpose Blood pressure (BP) control is strongly recommended, but BP control rate has not been well studied in patients with stroke. We evaluated the BP control rate with timasartan-based antihypertensive therapy initiated in patients with recent cerebral ischemia. Methods This multicenter, prospective, single-arm trial involved 27 centers in South Korea. Key inclusion criteria were recent cerebral ischemia within 90 days and high BP [systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg]. BP lowering was initiated with fimasartan. BP management during the follow-up was at the discretion of the responsible investigators. The primary endpoint was the target BP goal achievement rate (<140/90 mm Hg) at 24 weeks. Key secondary endpoints included achieved BP and BP changes at each visit, and clinical events (ClinicalTriaLs.gov Identifier: NCT03231293). Results Of 1,035 patients enrolled, 1,026 were included in the safety analysis, and 951 in the efficacy analysis. Their mean age was 64.1 years, 33% were female, the median time interval from onset to enrollment was 10 days, and the baseline SBP and DBP were 162.3 +/- 16.0 and 92.2 +/- 12.4 mm Hg (mean +/- SD). During the study period, 55.5% of patients were maintained on fimasartan monotherapy, and 44.5% received antihypertensive therapies other than fimasartan monotherapy at at least one visit. The target BP goal achievement rate at 24-week was 67.3% (48.6% at 4-week and 61.4% at 12-week). The mean BP was 139.0/81.8 +/- 18.3/11.7, 133.8/79.2 +/- 16.4/11.0, and 132.8/78.5 +/- 15.6/10.9 mm Hg at 4-, 12-, and 24-week. The treatment-emergent adverse event rate was 5.4%, including one serious adverse event. Conclusions Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated. | Hong, Keun-Sik; Kwon, Sun Uck; Park, Jong-Ho; Cha, Jae-Kwan; Jung, Jin-Man; Kim, Yong-Jae; Lee, Kyung Bok; Sohn, Sung Il; Lee, Yong-Seok; Rha, Joung-Ho; Kwon, Jee-Hyun; Han, Sang Won; Kim, Bum Joon; Koo, Jaseong; Choi, Jay Chol; Sung, Sang Min; Lee, Soo Joo; Park, Man-Seok; Ahn, Seong Hwan; Bang, Oh Young; Hwang, Yang-Ha; Nam, Hyo Suk; Park, Jong-Moo; Bae, Hee-Joon; Kim, Eung Gyu; Lee, Kyung-Yul; Oh, Mi Sun | Inje Univ, Ilsan Paik Hosp, Dept Neurol, 170 Juhwa Ro, Goyang 10380, South Korea; Univ Ulsan, Asan Med Ctr, Dept Neurol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea; Hanyang Univ, Myongji Hosp, Dept Neurol, Coll Med, Goyang, South Korea; Dong A Univ Hosp, Dept Neurol, Busan, South Korea; Korea Univ, Dept Neurol, Ansan Hosp, Ansan, South Korea; Catholic Univ Korea, Dept Neurol, Eunpyeong St Marys Hosp, Seoul, South Korea; Soonchunhyang Univ Hosp, Dept Neurol, Seoul, South Korea; Keimyung Univ, Dept Neurol, Dongsan Hosp, Daegu, South Korea; Seoul Natl Univ, Dept Neurol, Boramae Med Ctr, Seoul Metropolitan Govt, Seoul, South Korea; Inha Univ Hosp, Dept Neurol, Incheon, South Korea; Ulsan Univ, Dept Neurol, Coll Med, Ulsan, South Korea; Inje Univ, Sanggye Paik Hosp, Dept Neurol, Coll Med, Seoul, South Korea; Catholic Univ Korea, Dept Neurol, Seoul St Marys Hosp, Seoul, South Korea; Jeju Natl Univ, Jeju Natl Univ Hosp, Dept Neurol, Sch Med, Jeju, South Korea; Pusan Natl Univ Hosp, Dept Neurol, Busan, South Korea; Eulji Univ, Daejeon Eulji Univ Hosp, Dept Neurol, Daejeon, South Korea; Chonnam Natl Univ, Dept Neurol, Med Sch & Hosp, Gwangju, South Korea; Chosun Univ, Dept Neurol, Sch Med, Gwangju, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Yonsei Univ, Dept Neurol, Coll Med, Seoul, South Korea; Eulji Univ, Uijeongbu Eulji Med Ctr, Dept Neurol, Sch Med, Uijongbu, South Korea; Seoul Natl Univ, Cerebrovasc Ctr, Dept Neurol, Bundang Hosp, Seongnam, South Korea; Inje Univ, Dept Neurol, Busan Paik Hosp, Busan, South Korea; Yonsei Univ, Gangnam Severance Hosp, Dept Neurol, Coll Med, Seoul, South Korea; Hallym Univ, Dept Neurol, Sacred Heart Hosp, Anyang, South Korea | choi, jo/O-5940-2014; Kim, Sang-Gyu/T-5925-2017; Kim, Yong-Jae/JQW-5758-2023; Kim, Jinkwon/AAR-6729-2021; HWANG, Yang-Ha/F-3068-2013; Jung, Jin-Man/LJL-8037-2024; Lee, Kyung-Yeol/B-9978-2011 | 7402515553; 7402624264; 55716977200; 7202455743; 15755814800; 55865497600; 55737448000; 36479287000; 56127771600; 6701393879; 26661940800; 55986909300; 57214661365; 8319326700; 7501392645; 12447103200; 57218256652; 7404490852; 57200401172; 7006620221; 7402311308; 57216373862; 8407334400; 7103223963; 35169942100; 57306378900; 24492191600 | nrhks455@gmail.com;sukwon@amc.seoul.kr; | JOURNAL OF CLINICAL NEUROLOGY | J CLIN NEUROL | 1738-6586 | 2005-5013 | 17 | 3 | SCIE | CLINICAL NEUROLOGY | 2021 | 2.566 | 71.9 | 0 | 2025-07-30 | 0 | 0 | blood pressure; prevention and control; stroke; fimasartan | SECONDARY PREVENTION; STROKE; REDUCTION; TRIAL; EFFICACY; ATTACK; RISK; SAFE | Fimasartan; Prevention and control; Stroke; lood pressure | alanine aminotransferase; aspartate aminotransferase; C reactive protein; creatinine; fimasartan; glucose; hemoglobin A1c; adult; adverse event; antihypertensive therapy; Article; atrial fibrillation; blood pressure regulation; brain ischemia; clinical practice; congestive heart failure; controlled study; coughing; diastolic blood pressure; disease severity; dizziness; drug efficacy; dyslipidemia; dyspepsia; faintness; female; follow up; headache; hospitalization; human; ischemic heart disease; lipid fingerprinting; major clinical study; male; middle aged; multicenter study; prospective study; prothrombin time; randomized controlled trial; risk factor; systolic blood pressure; urea nitrogen blood level | English | 2021 | 2021-07 | 10.3988/jcn.2021.17.3.344 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Impact of an Education Program for Caregivers of Patients with Alzheimer's Disease on Treatment Discontinuation and Compliance in Korea | Background and Purpose Reportedly 30-50% of patients being treated fir chronic illnesses do not adhere to their medication regimen. We assessed the impact of a nurse-led education program for caregivers of Korean de novo Alzheimer's disease patients who had newly been prescribed donepezil. Methods This multicenter study analyzed 93 participants in a caregiver education group and 92 participants in a caregiver no-education group. At every visit up to the end of the study (1 year), caregivers in the education group were given educational brochures regarding Alzheimer's disease and the efficacy and adverse events of donepezil treatment. The primary endpoint was the discontinuation rate of donepezil treatment during the 1-year observation period. The secondary endpoints included the effect of education on compliance with donepezil treatment assessed at each visit using a clinician rating scale (CRS) and visual analog scale (VAS), and changes from baseline in cognitive assessment tests. Results The donepezil discontinuation rates at 1 year were 5.38% (5/93) and 6.52% (6/92) in the caregiver education and no-education groups, respectively (p=0.742). No significant between-group differences in donepezil compliance rates on the CRS and VAS were observed, but significant changes were observed in some cognitive tests from baseline to the end of the study. Conclusions Caregiver education had no significant effect on treatment discontinuation, but this may have been due to the low severity of cognitive impairment among the included population at baseline. In addition, the low discontinuation rates meant that no significant difference hi treatment compliance was observed. | Kim, Hee-Jin; Shim, Yong S.; Park, Kee Hyung; Lee, Chan-Nyoung; Jung, San; Yoon, Soo Jin; Jeong, Seul-Ki; Jeong, Jee Hyang; Choi, Seong Hye; Kim, Eun-Joo; Jang, Jae-Won; Kang, Kyunghun; Yang, YoungSoon; Kim, SangYun | Hanyang Univ, Coll Med, Dept Neurol, Seoul, South Korea; Catholic Univ Korea, Coll Med, Dept Neurol, Eunpyeong St Marys Hosp, Seoul, South Korea; Gachon Univ, Coll Med, Dept Neurol, Gil Hosp, Incheon, South Korea; Korea Univ, Coll Med, Dept Neurol, Anam Hosp, Seoul, South Korea; Hallym Univ, Kangnam Sacred Heart Hosp, Dept Neurol, Med Ctr, Seoul, South Korea; Eulji Univ, Eulji Univ Hosp, Dept Neurol, Sch Med, Daejeon, South Korea; Chonbuk Natl Univ, Dept Neurol, Sch Med, Jeonju, South Korea; Ewha Womans Univ, Dept Neurol, Seoul Hosp, Seoul, South Korea; Inha Univ, Dept Neurol, Sch Med, Incheon, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Neurol, Sch Med, Busan, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Neurol, Med Res Inst, Busan, South Korea; Kangwon Natl Univ, Kangwon Natl Univ Hosp, Dept Neurol, Coll Med, Chunchon, South Korea; Kyungpook Natl Univ, Sch Med, Dept Neurol, Daegu, South Korea; Soonchunhyang Univ, Cheonan Hosp, Dept Neurol, Coll Med, Cheonan, South Korea; Seoul Natl Univ, Dept Neurol, Coll Med, Seongnam, South Korea; Seoul Natl Univ, Bundang Hosp, Clin Neurosci Ctr, Seongnam, South Korea | Jeong, Seul-Ki/KSL-7574-2024; Kim, Sang/J-5400-2012; Jeong, Seul-ki/KSL-7574-2024; Kim, EunJoo/KIB-8989-2024; Yang, Yijian/G-1580-2016; Kim, Hee-Jin/P-1903-2015 | 58365187300; 26027624100; 7408065966; 54179516000; 9045212800; 55382315500; 8578821400; 7402045750; 15838894900; 57204538113; 56457145600; 55365592200; 37032348800; 7601593906 | neuroksy@snu.ac.kr; | JOURNAL OF CLINICAL NEUROLOGY | J CLIN NEUROL | 1738-6586 | 2005-5013 | 17 | 3 | SCIE | CLINICAL NEUROLOGY | 2021 | 2.566 | 71.9 | 0.37 | 2025-07-30 | 4 | 4 | Alzheimer's disease; caregiver education; dementia; Korea; treatment compliance | MEDICATION ADHERENCE; DEMENTIA; PREVALENCE; DONEPEZIL; CHINA | Alzheimer’s disease; Caregiver education; Dementia; Korea; Treatment compliance | English | 2021 | 2021-07 | 10.3988/jcn.2021.17.3.368 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Increasing Trends in the Incidence and Prevalence of Epilepsy in Korea | Background and Purpose There have been few reports on recent trends in the occurrence of epilepsy. The aim of this study was to estimate the incidence and prevalence of epilepsy and analyze their annual trends in Korea over the period 2009-2017. Methods This nationwide population-based study was carried out using the National Health Insurance Service of Korea database. A prevalent case was defined as one of a patient receiving a prescription of anticonvulsants under the diagnostic codes for epilepsy or seizure. An incident case was ascertained by confirming the absence of any epilepsy-related diagnostic codes and anticonvulsant prescription for 2 years or more before the operational definition for a prevalent case was met.. Alternative operational definitions for epilepsy were tested. The temporal trends of the incidence and prevalence of epilepsy were analyzed using a Poisson regression model, and are expressed as average annual percentage changes (AAPCs). Results The incidence of epilepsy increased from 28.7/100,000 persons in 2009 to 35.4/100,000 persons in 2017. The prevalence increased gradually from 3.4/1,000 persons in 2009 to 4.8/1,000 persons in 2017. These increasing trends were more evident among elderly subjects aged >= 75 years and in those who had codes for epilepsy or seizure as an additional diagnosis. Age standardization revealed a less prominent but still increasing trend in both incidence (AAPC=0.48%) and prevalence (AAPC=3.11%). Conclusions There have been increasing trends in both the prevalence and incidence of epilepsy in Korea between 2009 and 2017. This finding appears to be related to societal aging and the high incidence of symptomatic epilepsy in the elderly population. | Jeon, Ji-Ye; Lee, Hyesung; Shin, Ju-Young; Moon, Hye-Jin; Lee, Seo-Young; Kim, Jae-Moon | Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea; Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Seoul, South Korea; Soonchunhyang Univ, Coll Med, Dept Neurol, Bucheon Hosp, 170 Jomaru Ro, Bucheon 14584, South Korea; Kangwon Natl Univ, Coll Med, Dept Neurol, Chunchon, South Korea; Kangwon Natl Univ, Interdisciplinary Grad Program Med Bigdata Conver, Chunchon, South Korea; Chungnam Natl Univ, Dept Neurol, Coll Med, Daejeon, South Korea | Kim, Yong-Jae/JQW-5758-2023; Lee, Hyesung/GPC-5111-2022 | 57194943660; 57203821417; 34267857100; 55201533100; 35262340000; 34769781900 | moonhyejin21@gmail.com;leeseoyoung@kangwon.ac.kr; | JOURNAL OF CLINICAL NEUROLOGY | J CLIN NEUROL | 1738-6586 | 2005-5013 | 17 | 3 | SCIE | CLINICAL NEUROLOGY | 2021 | 2.566 | 71.9 | 1.65 | 2025-07-30 | 17 | 20 | epilepsy; epidemiology; incidence; prevalence; trend | UNPROVOKED SEIZURES; TREATED EPILEPSY; RURAL AREA; COMMUNITY; EPIDEMIOLOGY; METAANALYSIS; DISTRICT; ICELAND; BURDEN | Epidemiology; Incidence; Prevalence; Trend; epilepsy | English | 2021 | 2021-07 | 10.3988/jcn.2021.17.3.393 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Review | Tinnitus Update | This article provides an update on tinnitus for audiologists and other clinicians who provide tinnitus-specific services. Tinnitus can be attributable to hearing loss, somatosensory system dysfunction, or auditory cortex dysfunction, with hearing loss being the most common cause and serious underlying pathologies being rare. Hearing loss does not always lead to tinnitus, and patients with tinnitus do not always suffer from hearing loss. The first scenario is explained by a so-called inhibitory gating mechanism, whereas the second assumes that all tinnitus sufferers have some degree of hearing impairment, which might not be detected in standard audiological examinations. The treatments should aim at symptomatic relief and management of associated distress. Current treatment options include pharmacotherapy, education, counseling, cognitive behavioral therapy, and sound therapy. | Hana, Byung In; Leeb, Ho Won; Ryu, Sanghyo; Kimd, Ji-Soo | Neurol Clin, Daegu, South Korea; Kyungpook Natl Univ, Dept Neurol, Daegu, South Korea; Haedong Hosp, Dept Neurol, 133 Taejong Ro, Busan 49035, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Neurol, Seongnam, South Korea | Kim, Ji-Soo/D-8744-2012; Ryu, Sanghyo/KCK-0912-2024 | 15062896700; 35337240700; 57221809954; 8055087900 | sanghyoryu@gmail.com; | JOURNAL OF CLINICAL NEUROLOGY | J CLIN NEUROL | 1738-6586 | 2005-5013 | 17 | 1 | SCIE | CLINICAL NEUROLOGY | 2021 | 2.566 | 71.9 | 1.37 | 2025-07-30 | 34 | 32 | tinnitus; hearing loss; treatment | HEARING-LOSS; PREVALENCE; MECHANISMS; MANAGEMENT; STIMULATION; EXPERIENCE; DIAGNOSIS | Hearing loss; Tinnitus; Treatment | English | 2021 | 2021-01 | 10.3988/jcn.2021.17.1.1 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Treatments for Convulsive and Nonconvulsive Status Epilepticus in Adults: An Expert Opinion Survey in South Korea | Background and Purpose The aim of this study was to survey the expert opinions on treatments for convulsive status epilepticus (CSE) and nonconvulsive status epilepticus (NCSE) in adults. Methods Forty-two South Korean epileptologists participated in this survey. They completed an online questionnaire regarding various patient scenarios and evaluated the appropriateness of medications used to treat CSE and NCSE. Results Initial treatment with a benzodiazepine (BZD) followed by either a second BZD or an antiepileptic drug (AED) monotherapy was the preferred treatment strategy. More than two-thirds of the experts used a second BZD when the first one failed, and consensus was reached for 84.8% of the survey items. The preferred BZD was intravenous (IV) lorazepam for the initial treatment of status epilepticus. IV fosphenytoin and IV levetiracetam were chosen for AED monotherapy after the failure of BZD. The treatments for NCSE were similar to those for CSE. Continuous IV midazolam infusion was the treatment of choice for iatrogenic coma in refractory CSE, but other AEDs were preferred over iatrogenic coma in refractory NCSE. Conclusions The results of this survey are consistent with previous guidelines, and can be cautiously applied in clinical practice when treating patients with CSE or NCSE. | Byun, Jung-Ick; Kim, Dong Wook; Kim, Keun Tae; Yang, Kwang Ik; Lee, Soon-Tae; Seo, Jong-Geun; No, Young Joo; Kang, Kyung Wook; Kim, Daeyoung; Cho, Yong Won; Kim, Jae-Moon | Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Sch Med, Dept Neurol, Seoul, South Korea; Konkuk Univ, Dept Neuroloy, Sch Med, Seoul, South Korea; Keimyung Univ, Dept Neurol, Sch Med, 1095 Dalgubeol Daero, Daegu 42601, South Korea; Soonchunhyang Univ, Cheonan Hosp, Dept Neurol, Coll Med, Cheonan, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Neurol, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Neurol, Daegu, South Korea; Samsung Noble Cty, Dept Neurol, Yongin, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Dept Neurol, Sch Med, Gwangju, South Korea; Chungnam Natl Univ Hosp, Dept Neurol, 282 Munhwa Ro, Daejeon 35015, South Korea | ; Lee, Soon-Tae/C-4663-2013; Kim, Yong-Jae/JQW-5758-2023; Kim, Keun Tae/IQU-1105-2023 | 55896913500; 57075285300; 57204465615; 55328263200; 8527655300; 16040307500; 6701791454; 57211333312; 57191361218; 55080335000; 34769781900 | neurocho@gmail.com;jmoonkim@cnu.ac.kr; | JOURNAL OF CLINICAL NEUROLOGY | J CLIN NEUROL | 1738-6586 | 2005-5013 | 17 | 1 | SCIE | CLINICAL NEUROLOGY | 2021 | 2.566 | 71.9 | 0.18 | 2025-07-30 | 2 | 2 | consensus; treatment; status epilepticus; nonconvulsive status epilepticus | REFRACTORY STATUS EPILEPTICUS; RANDOMIZED-TRIAL; GUIDELINE; MIDAZOLAM; LORAZEPAM; ONSET; MANAGEMENT; DIAZEPAM; RISK | Consensus; Nonconvulsive status epilepticus; Status epilepticus; Treatment | anticonvulsive agent; benzodiazepine; clonazepam; fosphenytoin sodium; lacosamide; levetiracetam; lorazepam; methylprednisolone; midazolam; phenytoin; valproic acid; adult; Article; coma; convulsion; electroencephalography; epileptic state; female; health survey; human; male; monotherapy; online analysis; practice guideline; questionnaire; South Korea; treatment failure | English | 2021 | 2021-01 | 10.3988/jcn.2021.17.1.20 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | The Role of Social Capital and Welfare in Absenteeism Across 26 OECD Countries Moderating Effect on Employment and Working Conditions | Objectives: This study attempted to investigate social contextual effect on the occurrence of workers' absenteeism. Methods: Survey data on 30,913 wage workers in 26 countries were linked to the indicators for social capital and welfare from the national database. Multi-level logistic regression was used for analyses. Results: Employment contract, atypical work, physical and psycho-social working conditions (effort and reward), social capital and welfare significantly explained the differences in occurrence of absenteeism across countries. Analysis of cross-level interactions revealed that macro indicators related to social capital, and public social and health expenditure had moderating effects on the relation between individual-level factors and absenteeism. Conclusion: High level of public spending on welfare policies and social bonding decrease the risk of absenteeism caused by vulnerable working environments, but it also worsen gaps in coping capabilities of workers in non-permanent contract and atypical work pattern. | Kwon, Min Jung | Kyungpook Natl Univ, Coll Nursing, 680 Gukchaebosang Ro, Daegu 41944, South Korea | 57200373594 | kmj1730@naver.com; | JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE | J OCCUP ENVIRON MED | 1076-2752 | 1536-5948 | 63 | 2 | SCIE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | 2021 | 2.306 | 72.1 | 0 | 2025-07-30 | 0 | 0 | absenteeism; atypical work; employment; social capital; social welfare; work environment | EFFORT-REWARD IMBALANCE; SICKNESS ABSENCE; EUROPEAN-UNION; HEALTH; UNEMPLOYMENT; PROTECTION; MORTALITY; PREDICTOR; CONTRACT; STRAIN | Absenteeism; Atypical work; Employment; Social capital; Social welfare; Work environment | Absenteeism; Employment; Humans; Organisation for Economic Co-Operation and Development; Social Capital; Social Welfare; absenteeism; article; employment contract; human; Organisation for Economic Co-operation and Development; reward; social bonding; social capital; social welfare; work environment; worker; employment; Organisation for Economic Co-operation and Development; social welfare | English | 2021 | 2021-02 | 10.1097/jom.0000000000002037 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Design and analysis of a novel spoke-type motor to reduce the use of rare-earth magnet materials | In this study, a novel design for a tilted spoke-type hybrid permanent magnet synchronous motor (TH-PMSM) that uses two types of permanent magnet (PM) materials is proposed to reduce the consumption of rare-earth PM materials. The key feature of this motor is securing space by tilting the permanent magnet, so that more PMs can be used in the limited rotor space. In addition, based on the centre axis of the rotor, the rare-earth magnets are positioned deeper inside than ferrite PMs to maximise the torque density and reduce the leakage magnetic flux that occurs around the centre of the rotor. Moreover, unlike ordinary spoke-type rotors, it is designed with an integral core like the rotor of the interior permanent magnet synchronous motor (IPMSM), so it is structurally safe even at high speeds. To ensure that the proposed motor is efficiently designed, the output torque, PM cost, cogging torque, and torque ripple were compared with those of the conventional rare-earth PM motors with the same overall dimensions. The validity of the proposed motor was verified by the results of a finite element method simulation and experiments on the fabricated motor. | Seok, Chang-Hoon; Choi, Hong-Soon; Seo, Jangho | Kyungpook Natl Univ, Sch Elect & Elect Engn, Daegu, South Korea; Kyungpook Natl Univ, Sch Automot Engn, Saniju, South Korea | 57581239400; 7404338767; 12791073600 | j.seo@knu.ac.kr; | IET ELECTRIC POWER APPLICATIONS | IET ELECTR POWER APP | 1751-8660 | 1751-8679 | 15 | 11 | SCIE | ENGINEERING, ELECTRICAL & ELECTRONIC | 2021 | 1.737 | 72.3 | 0.28 | 2025-07-30 | 5 | 6 | TORQUE DENSITY; OPTIMIZATION; MACHINES; FERRITE | Hybrid materials; Magnetic leakage; Rare earths; Synchronous motors; Torque; Design and analysis; Key feature; Leakage magnetic flux; Novel design; Permanent magnet materials; Permanent Magnet Synchronous Motor; Rare earth magnet; Rare earth permanent magnet; Rare-earth magnet materials; Torque density; Permanent magnets | English | 2021 | 2021-11 | 10.1049/elp2.12109 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Review | Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions | Introduction Ibrutinib is a highly effective drug for patients with chronic lymphocytic leukemia (CLL), and is well tolerated even by older patients and those unfit to receive conventional immuno-chemotherapy. Areas covered The occurrence of adverse events was revealed as a major cause of ibrutinib failure in the real-world. Ibrutinib-induced lymphocytosis carries the risk of an untimely interruption of therapy because it may be misinterpreted as disease progression. In addition, drug interactions can worsen ibrutinib-associated toxicities by increasing the plasma concentration of ibrutinib. In this review, we present a case of major hemorrhage and atrial fibrillation (AF) during ibrutinib use and summarize the adverse events associated with ibrutinib. Furthermore, the practical management of ibrutinib-associated toxicities was covered with reference to a drug interaction mechanism. Expert opinion Clinicians should examine the prescribed drugs prior to ibrutinib initiation and carefully monitor toxicities while taking ibrutinib. A reduced dose of ibrutinib with the concurrent use of CYP3A inhibitors such as antifungal agents could be an attractive strategy to reduce toxicities and may confer financial benefits. Reducing unexpected toxicities is as significant as achieving treatment response in the era of life-long therapy with ibrutinib in patients with CLL. | Cho, Hee Jeong; Baek, Dong Won; Kim, Juhyung; Lee, Jung Min; Moon, Joon Ho; Sohn, Sang Kyun | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea | Lee, Jung-Min/L-8227-2016 | 57216754907; 57191874272; 58739544500; 57211561890; 56568642700; 13310226800 | sksohn@knu.ac.kr; | EXPERT REVIEW OF HEMATOLOGY | EXPERT REV HEMATOL | 1747-4086 | 1747-4094 | 14 | 9 | SCIE | HEMATOLOGY | 2021 | 2.819 | 72.4 | 0.26 | 2025-07-30 | 4 | 5 | Chronic lymphocytic leukemia (CLL); ibrutinib; atrial fibrillation (AF); hemorrhage; invasive fungal infection; coronavirus disease (COVID-19); lymphocytosis; drug interaction; dose modification strategy | BRUTON TYROSINE KINASE; ATRIAL-FIBRILLATION; INFECTIOUS COMPLICATIONS; VENTRICULAR-TACHYCARDIA; INHIBITOR IBRUTINIB; PLATELET ACTIVATION; TREATED PATIENTS; OPEN-LABEL; FOLLOW-UP; THERAPY | atrial fibrillation (AF); Chronic lymphocytic leukemia (CLL); coronavirus disease (COVID-19); dose modification strategy; drug interaction; hemorrhage; ibrutinib; invasive fungal infection; lymphocytosis | Adenine; Aged; COVID-19; Disease Management; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; acetylsalicylic acid; amiodarone; antiarrhythmic agent; antifungal agent; fludarabine; ibrutinib; lactate dehydrogenase; prednisolone; venetoclax; adenine; ibrutinib; piperidine derivative; protein kinase inhibitor; absolute lymphocyte count; aged; anemia; angina pectoris; atrial fibrillation; bleeding; bone marrow biopsy; cancer patient; case report; chronic lymphatic leukemia; clinical article; clinician; coronavirus disease 2019; drug blood level; drug dose reduction; drug mechanism; drug withdrawal; dyspnea; erythrocyte count; fatigue; heart arrhythmia; heart palpitation; heart tamponade; human; human tissue; hypoxemia; infection prevention; leukemia relapse; leukemia remission; lymphocytosis; male; multiple cycle treatment; nonhuman; pericardial effusion; pericardiocentesis; perioperative period; positron emission tomography-computed tomography; Review; salvage therapy; systemic mycosis; thrombocytopenia; treatment interruption; treatment response; adverse drug reaction; chronic lymphatic leukemia; complication; disease management; drug interaction | English | 2021 | 2021-09-02 | 10.1080/17474086.2021.1967139 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Posterior properties under matching priors for generalized gamma distribution | Recently, the overall reference prior has been proposed for parameters of the generalized gamma distribution. As an alternative, here we develop a matching prior that provides the same coverage probability asymptotically as a Bayesian credible interval with the corresponding frequentist counterpart, and subsequently show that this matching prior yields proper posteriors. In addition, we find that the overall reference prior is not a first-order matching prior. Simulation studies show that the derived matching priors perform better than the overall reference prior in meeting the target coverage probabilities, and meets the target coverage probabilities well even for a small sample size. | Kang, Sang Gil; Lee, Woo Dong; Kim, Yongku | Sangji Univ, Dept Comp & Data Inforamt, Wonju, South Korea; Daegu Haany Univ, Dept Cosmeceut Engn, Gyongsan, South Korea; Kyungpook Natl Univ, Dept Stat, Daegu, South Korea | 56119861400; 8328822200; 47962102500 | kim.1252@knu.ac.kr; | COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION | COMMUN STAT-SIMUL C | 0361-0918 | 1532-4141 | 50 | 4 | SCIE | STATISTICS & PROBABILITY | 2021 | 1.162 | 72.4 | 0 | 2025-07-30 | 0 | 0 | Generalized gamma distribution; Matching prior; Overall reference prior | Generalized gamma distribution; Matching prior; Overall reference prior | Communication; Computer simulation; Statistics; Coverage probabilities; Credible interval; Generalized gamma distribution; Matching prior; Posterior property; Reference prior; Simulation studies; Small Sample Size; Probability distributions | English | 2021 | 2021-04-16 | 10.1080/03610918.2019.1580725 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Review | Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia | Introduction The long-term survival of relapsed/refractory (R/R) adult T-cell acute lymphoblastic leukemia (T-ALL) is quite poor, and early T-cell precursor (ETP) ALL has recently been described as a high-risk T-ALL subgroup. However, the optimal therapeutic approach to R/R adult T-ALL remains poorly established. Areas covered At present, cytoreductive therapy followed by allogeneic stem cell transplantation (allo-SCT) is considered to be the most clinically relevant and curative modality for R/R T-ALL. Above all, achieving minimal residual disease (MRD) is a key factor for successful allo-SCT and maintaining long-term remission for R/R patients. As a salvage regimen, nelarabine is the only therapy that was specifically approved for use in patients with R/R T-ALL. A combination of conventional chemotherapeutic agents and novel agents, such as venetoclax, can be used as alternatives for cytoreduction and bridging to transplantation. Relevant literatures published in the last 30 years were searched from PubMed to review the topic of T-ALL, and allo-SCT. Expert opinion An effective salvage regimen, to achieve negative MRD, followed by allo-SCT is currently the best way to improve the clinical outcomes of adult R/R T-ALL. Moreover, posttransplant therapies, such as prophylactic or preemptive donor leukocyte infusion and hypomethylating agents, need to be considered as sequential therapy. | Baek, Dong Won; Lee, Jung Min; Kim, Juhyung; Cho, Hee Jeong; Moon, Joon Ho; Sohn, Sang Kyun | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, Daegu, South Korea | Lee, Jung-Min/L-8227-2016 | 57191874272; 57211561890; 58739544500; 57216754907; 56568642700; 13310226800 | sksohn@knu.ac.kr; | EXPERT REVIEW OF HEMATOLOGY | EXPERT REV HEMATOL | 1747-4086 | 1747-4094 | 14 | 8 | SCIE | HEMATOLOGY | 2021 | 2.819 | 72.4 | 0.42 | 2025-07-30 | 8 | 9 | Acute lymphoblastic leukemia; post-transplant therapy; relapsed; refractory; stem cell transplantation; T-cell | DONOR LYMPHOCYTE INFUSION; MINIMAL RESIDUAL DISEASE; ACUTE MYELOID-LEUKEMIA; HYPER-CVAD; ACTIVATING MUTATIONS; SALVAGE THERAPY; CLINICAL-TRIAL; WORKING PARTY; PHASE-II; NELARABINE | Acute lymphoblastic leukemia; post-transplant therapy; relapsed/refractory; stem cell transplantation; T-cell | Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Neoplasm, Residual; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; T-Lymphocytes; asparaginase; busulfan; cyclophosphamide; cytarabine; daunorubicin; dexamethasone; doxorubicin; etoposide; ifosfamide; mesna; nelarabine; prednisolone; venetoclax; vincristine; acute lymphoblastic leukemia; adult; allogeneic stem cell transplantation; cancer patient; cancer recurrence; case report; chronic graft versus host disease; clinical article; clinical outcome; consolidation chemotherapy; donor lymphocyte infusion; female; haploidentical transplantation; human; induction chemotherapy; infection; leukemia remission; leukocytosis; long term survival; lymphadenopathy; male; minimal residual disease; multiple cycle treatment; myeloablative conditioning; pancytopenia; Review; treatment response; young adult; acute lymphoblastic leukemia; adoptive immunotherapy; hematopoietic stem cell transplantation; T lymphocyte | English | 2021 | 2021-08-03 | 10.1080/17474086.2021.1960817 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Bariatric surgery versus medical therapy in Korean obese patients: prospective multicenter nonrandomized controlled trial (KOBESS trial) | Purpose: The aim of this study was to show that bariatric surgery (BS) is more effective than medical therapy (MT) in Asian obese patients. Methods: In this prospective, multicenter, nonrandomized, controlled trial, obese patients with body mass index of >= 35 kg/m(2) or 30.0-34.9 kg/m(2) with obesity-related comorbidities were assigned to undergo BS, such as laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass, or MT. Patients who underwent BS were evaluated 4, 12, 24, and 48 weeks after surgery, whereas patients who received MT were monitored at a hospital every 6 weeks for 1 year. At each visit, weight, waist and hip circumference, and blood pressure were measured, and patients underwent physical examination and laboratory testing. Health-related quality of life (HQOL) was investigated using Euro QOL-5 Dimension, Impact of Weight on Quality of Life questionnaire-Lite and Obesity-related Problems scale. Results: The study included 264 patients from 13 institutions; of these, 64 underwent BS and 200 received MT. Of the patients who underwent BS, 6.3% experienced early complications. Relative weight changes from baseline to 48 weeks were significantly greater in the BS than in the MT group (26.9% vs. 2.1%, P < 0.001), as were the rates of remission of diabetes (47.8% vs. 16.7%, P = 0.014), hypertension (60.0% vs. 26.1%, P < 0.001), and dyslipidemia (63.2% vs. 22.0%, P < 0.001). HQOL was better in the BS than in the MT group at 48 weeks. Conclusion: BS was safe and effective in Korean obese patients, with greater weight reduction, remission of comorbidities, and quality of life improvement than MT. | Park, Do Joong; An, Sena; Park, Young Suk; Lee, Joo-Ho; Lee, Hyuk-Joon; Ha, Tae Kyung; Kim, Yong-Jin; Ryu, Seung-Wan; Han, Sang-Moon; Yoo, Moon-Won; Park, Sungsoo; Han, Sang-Uk; Kang, Jae-Heon; Kwon, Jin-Won; Heo, Yoonseok | Seoul Natl Univ Hosp, Dept Surg, Seoul, South Korea; Seoul Natl Univ, Dept Surg, Bundang Hosp, Seongnam, South Korea; Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu, South Korea; Natl Evidence Based Healthcare Collaborating Agcy, Seoul, South Korea; Eulji Univ, Nowon Eulji Med Ctr, Dept Surg, Seoul, South Korea; Hanyang Univ, Dept Surg, Coll Med, Seoul, South Korea; Soonchunhyang Univ Hosp, Dept Surg, Seoul, South Korea; H Yangji Hosp, Dept Surg, Seoul, South Korea; Keimyung Univ, Dept Surg, Dongsan Hosp, Daegu, South Korea; CHA Gangnam Med Ctr, Dept Surg, Seoul, South Korea; Cheil Gen Hosp, Dept Surg, Seoul, South Korea; Asan Med Ctr, Dept Surg, Seoul, South Korea; Korea Univ, Coll Med, Dept Surg, Anam Hosp, Seoul, South Korea; Ajou Univ Hosp, Dept Surg, Suwon, South Korea; Kangbook Samsung Hosp, Dept Family Med, Seoul, South Korea; Inha Univ Hosp, Dept Surg, 100 Inha Ro, Incheon 22212, South Korea | ; Ha, Tae/P-1706-2015; Park, Susan/JRY-5671-2023; Kim, Yong-Jin/J-2745-2012; Park, Sun-Young/B-4634-2014; Kim, Il Young/LLK-4732-2024; Ha, Tae Kyung/P-1706-2015 | 14319341400; 57210320106; 57223380460; 55689891300; 7501481303; 23049990400; 56588394200; 55420795900; 56121169800; 23020267900; 57187346700; 35798267700; 57217443426; 16202951700; 39361359300 | gshur@inha.ac.kr; | ANNALS OF SURGICAL TREATMENT AND RESEARCH | ANN SURG TREAT RES | 2288-6575 | 2288-6796 | 101 | 4 | SCIE | SURGERY | 2021 | 1.766 | 72.5 | 0.99 | 2025-07-30 | 7 | 7 | Asia; Bariatric surgery; Metabolic diseases; Obesity | LAPAROSCOPIC-SLEEVE-GASTRECTOMY; QUALITY-OF-LIFE; CONVENTIONAL THERAPY; GASTRIC BYPASS; SUBJECTS SOS; HEALTH; HISTORY; INTERVENTION; OUTCOMES | Asia; Bariatric surgery; Metabolic diseases; Obesity | English | 2021 | 2021-10 | 10.4174/astr.2021.101.4.197 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Current status of initial antibiotic therapy and analysis of infections in patients with solitary abdominal trauma: a multicenter trial in Korea | Purpose: Proper use of antibiotics during emergency abdominal surgery is essential in reducing the incidence of surgical site infection. However, no studies have investigated the type of antibiotics and duration of therapy in individuals with abdominal trauma in Korea. We aimed to investigate the status of initial antibiotic therapy in patients with solitary abdominal trauma. Methods: From January 2015 to December 2015, we retrospectively analyzed the medical records of patients with solitary abdominal trauma from 17 institutions including regional trauma centers in South Korea. Both blunt and penetrating abdominal injuries were included. Time from arrival to initial antibiotic therapy, rate of antibiotic use upon injury mechanism, injured organ, type, and duration of antibiotic use, and postoperative infection were investigated. Results: Data of the 311 patients were collected. The use of antibiotic was initiated in 96.4% of patients with penetrating injury and 79.7% with blunt injury. Initial antibiotics therapy was provided to 78.2% of patients with solid organ injury and 97.5% with hollow viscus injury. The mean day of using antibiotics was 6 days in solid organ injuries, 6.2 days in hollow viscus. Infection within 2 weeks of admission occurred in 36 cases. Infection was related to injury severity (Abbreviated Injury Scale of >3), hollow viscus injury, operation, open abdomen, colon perforation, and RBC transfusion. There was no infection in cases with laparoscopic operation. Duration of antibiotics did not affect the infection rate. Conclusion: Antibiotics are used extensively (84.2%) and for long duration (6.2 days) in patients with abdominal injury in Korea. | Lee, Gil Jae; Kyoung, Kyu-Hyouck; Kim, Ki Hoon; Kim, Namryeol; Sul, Young Hoon; Lim, Kyoung Hoon; Hong, Suk-Kyung; Cho, Hangjoo | Gachon Univ, Coll Med, Dept Traumatol, Gil Med Ctr, Incheon, South Korea; Univ Ulsan, Ulsan Univ Hosp, Dept Surg, Coll Med, Ulsan, South Korea; Univ Ulsan, Ulsan Univ Hosp, Trauma Ctr, Coll Med, Ulsan, South Korea; Inje Univ, Haeundae Paik Hosp, Dept Gen Surg, Busan, South Korea; Korea Univ, Dept Trauma Surg, Guro Hosp, Seoul, South Korea; Chungbuk Natl Univ Hosp, Dept Trauma Surg, Cheongju, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Surg, Daegu, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Div Acute Care Surg,Dept Surg, Seoul, South Korea; Catholic Univ Korea, Coll Med, Uijeongbu St Mary Hosp, Dept Trauma Surg, 271 Cheonbo Ro, Seoul 11765, South Korea | Kim, Tae-Hee/AAN-9079-2021; Lee, Gil/AAC-5498-2022; Hong, Suk-Kyung/B-5677-2015 | 55694125400; 41261667100; 39361679400; 57222083433; 57190188271; 25630643100; 36514753900; 27267449100 | surgeryman@catholic.ac.kr; | ANNALS OF SURGICAL TREATMENT AND RESEARCH | ANN SURG TREAT RES | 2288-6575 | 2288-6796 | 100 | 2 | SCIE | SURGERY | 2021 | 1.766 | 72.5 | 0.33 | 2025-07-30 | 2 | 2 | Abdoimnal Injury; Anti-bacterial agents; Blunt injury; Penetrating injury | ANTIMICROBIAL PROPHYLAXIS; GUIDELINES; DURATION; RISK | Abdoimnal injury; Anti-bacterial agents; Blunt injury; Penetrating injury | English | 2021 | 2021-02 | 10.4174/astr.2021.100.2.119 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: